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RESUMO
O tratamento do carcinoma do pulmão de não pequenas células avançado mudou com o desenvolvimento de novas terapêuticas 
moleculares, tais como os inibidores da tirosina quinase. Um destes exemplos é o crizotinib que tem como alvo inibir a translocação 
do gene da quinase do linfoma, que se encontra presente em 2% a 7% dos casos de carcinoma do pulmão de não pequenas 
células. Apesar destes novos tratamentos mostrarem resultados promissores, a ocorrência de doença pulmonar intersticial como efeito 
secundário pode ser problemática. O diagnóstico de doença pulmonar intersticial associada ao tratamento é de difícil confirmação, 
o que tornou a tomografia computorizada uma importante ferramenta no diagnóstico. Pretendemos alertar para a doença pulmonar 
intersticial relacionada com os inibidores da tirosina quinase através da apresentação do primeiro caso de uma doente portuguesa 
tratada com crizotinib para carcinoma do pulmão de não pequenas células que desenvolveu doença pulmonar intersticial.
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ABSTRACT
The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine 
kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets 
an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 
7% of non-small-cell lung cancer cases. Although these new therapies have shown promising results, the occurrence of interstitial lung 
disease as a side effect could be problematic. As the diagnosis of drug-related-interstitial lung disease is difficult to make, computed 
tomography is an important diagnostic tool. The recognition of computed tomography manifestations of tyrosine kinase inhibitors 
-induced interstitial lung disease is the key for an early recognition and management of this pulmonary toxicity. We aim to raise 
awareness of tyrosine kinase inhibitors -induced interstitial lung disease, by reporting the first case of a Portuguese patient treated with 
crizotinib for non-small-cell lung cancer who developed drug-induced interstitial lung disease.
Keywords: Carcinoma, Non-Small-Cell Lung/drug therapy; Crizotinib; Lung Diseases, Interstitial/chemically induced; Lung Diseases, 
Interstitial/diagnosis; Tomography, X-Ray Computed
INTRODUCTION
 Although new target therapies, like tyrosine kinase in-
hibitors (TKIs), have created a paradigm shift in the treat-
ment of advanced non-small-cell lung cancer (NSCLC), the 
occurrence of severe adverse events remains problematic.1 
One of the severe adverse events described was intersti-
tial lung disease (ILD).2,3 ILD may appear during the initial 
treatment or years later, and the onset of symptons may be 
acute or insidious. Computed tomography (CT) is crucial to 
achieve an early diagnosis and to detect subtle parenchy-
mal diseases.3
 Crizotinib is an orally available small-molecule inhibitor 
of anaplastic lymphoma (ALK) tyrosine kinase, and showed 
promising results for treating stage IV NSCLC, with the fu-
sion gene comprising portions of the ALK and the echino-
derm microtubule-associated protein-like 4 (EML4).2 This 
fusion gene is expressed in 2% - 7% of the NSCLC cases, 
predominantly in patients with reduced or no exposure to 
tobacco, and with adenocarcinoma.1,4
 We present a case of Crizotinib-induced ILD in a patient 
with stage IV NSCLC, where the diagnosis was prompted 
by a characteristic ground-glass opacity (GGO) finding in 
high-resolution computed tomography (HRCT) of the tho-
rax.
CASE REPORT
 A 40-year-old woman, with history of smoking (25 pack-
years), was diagnosed with stage IV lung adenocarcinoma 
with metastatic lesions. The tumor was tested for epidermal 
growth factor receptor (EGFR) mutation and ALK rearrange-
ment, but it took one month for the results to be known. In 
this setting, she started cytotoxic chemotherapy with cys-
taplatin and pemetrexed. After one cycle of treatment she 
had progression and the fluorescence in situ hybridization 
analysis revealed the EML4-ALK gene fusion, so she initi-
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 After two months of crizotinib therapy, the patient pre-
sented with productive cough, fatigue, very high c-reactive 
protein serum level, and low oxygen saturation (87%). For 
this reason, she was admitted to the respiratory department 
with the presumed diagnosis of pneumonia, and started em-
piric antibiotics. The chest radiography showed right lower 
zone opacification, within the medium lobe; a right atelecta-
sis, suggested by the elevation of the right diaphragm, and 
the right shift of mediastinum; and findings related to lung 
cancer, such as regional opacities associated with reticular 
interstitial opacities (Fig. 1). Sputum and blood cultures and 
serologic tests were done. The cultures and the serology 
tests came negative, and the HRCT of the thorax showed: 
a crazy-paving pattern with bilateral and geographic GGO, 
well delimitated from the normal lung, and a fine reticu-
lar pattern related to an interlobular and intralobular sep-
tal thickening (Fig. 2). Meanwhile, the respiratory distress 
worsened, and she was admitted in the intensive care unit 
(ICU).
 A crizotinib-induced ILD was assumed (grade 4 based 
on CTCAE V4). 5 Crizotinib was immediately discontinued, 
and corticosteroids were initiated. After four days in ICU, 
she showed clinical and radiological improvement (Fig. 3). 
Figure 1 – Chest radiography: PA view: right lower zone opacifica-
tion, limited superiorly by the small fissure, with silhouette sign with 
the right contour of the heart, which indicates its location in the 
medium lobe. The elevation of the right diaphragm and right shift 
of mediastinum suggests a right atelectasis. We also see discrete 
bilateral, regional opacities within reticular interstitial opacities.
Figure 2 – HRCT of the thorax: (A) the bilateral reticular interstitial opacities are more pronounced; (B) and (C) findings related to the tu-
mor: right-lower-lobe irregular and heterogeneous mass, that enhances after contrast administration; right hilar and mediastinal enlarged 
lymph nodes; right medium lobe atelectasis is seen, which may be related to obstructive pneumonitis; (D) bilateral, regional ground-glass 
opacities in association with interlobular and intralobular septal thickening, simulating a crazy-paving pattern. These findings are related 
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Two weeks later, she underwent another HRCT of the tho-
rax that showed partial response, with few ground-glass 
opacities.
 With the discontinuation of Crizotinib, the disease pro-
gressed and she died six months after the initial lung cancer 
diagnosis.
DISCUSSION
 The ILD related to TKIs used in advanced NSCLC treat-
ment has already been studied and recognized. Crizotinib-
induced ILD is considered a rare event,6 however, nowa-
days, there are more cases of Crizotinib-induced ILD re-
ported, most of them in Asian patients with no related smok-
ing exposure.1,7-12
 Cough, fever and dyspnea may be present in patients 
with advanced NSCLC treated with TKIs, like in our case, 
but are usually non-specific.3 In addition, the onset of pul-
monary complications is unpredictable and there have been 
some life-threatening cases.3 In this setting, CT is an im-
portant diagnostic tool, and the recognition of TKIs-induced 
ILD imaging features leads to an early diagnosis, and the 
correct management of these patients.4
 In order to understand the CT manifestations of TKIs-
induced ILD, we shall divide the pathogenic process be-
tween acute and chronic mechanisms. Usually, in the acute 
process, a diffuse alveolar damage is the histopathologic 
finding.3 On the contrary, the inappropriate regeneration of 
the injured epithelium leads to the stimulation of fibroblasts 
in the chronic process.3
 The evaluation of drug-induced ILD CT features should 
include the distribution and the pattern of parenchymal le-
sions, such as interlobular septal thickening, honeycomb-
ing, ground-glass opacities (GGO), reticular lesions, trac-
tion bronchiectasis, and small centrilobular nodules. Usually 
these lesions appear with a patchy and bilateral distribution, 
and generally reflect the underlying histopathological pro-
cess.13
 Drug-induced ILD can present as diffuse alveolar dam-
age (DAD), nonspecific interstitial pneumonia (NSIP), 
bronchiolitis obliterans organizing pneumonia (BOOP), eo-
sinophilic pneumonia, obliterative bronchiolitis, pulmonary 
hemorrhage, and edema.13 Regarding TKI’s-induced ILD 
classification, Min JH et al suggest six categories: DAD or 
acute interstitial pneumonia; bronchiolitis obliterans; BOOP; 
hypersensitivity pneumonia; NSIP; and UIP.3
 DAD is the most common manifestation of drug-induced 
ILD, resulting from necrosis of endothelial cells, and type 
II pneumocytes.13 In terms of histopathology, DAD can be 
divided into acute, and chronic phases: the acute phase 
often appears at the first week of lung injury; the chronic 
and reparative phase, typically occurs after 1 - 2 weeks.13 
The patients usually present with dyspnea, cough, and 
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Figure 3 – HRCT of the thorax two weeks after crizotinib discontinuation: (A) there is progression of the tumor: growth of the right lower 
lobe opacification and new right pleural effusion; (B), (C) and (D) we can partial see almost total remission of the bilateral ground-glass 
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fever. The chest x-ray shows bilateral heterogeneous opaci-
ties, commonly in the mid and lower lung, that progress to 
diffuse opacification.13 On HRCT, the early phases of DAD 
manifest as scattered or diffuse bilateral areas of GGO, and 
regions of consolidation involving the dependent lung re-
gions.15,16 Some patchy areas of bilateral GGO in associa-
tion with some lung sparing areas produce a geographical 
appearance. Confluent areas of GGO in association with 
reticular opacities result in a crazy-paving pattern.14, In the 
advanced phases, HRCT shows progressive fibrosis, with 
architectural distortion, and honeycombing.13 Our patient’s 
HRCT showed typical findings of DAD (Figs. 2 and 3).
 Any chemotherapy agent can be associated with over-
lapping CT patterns. Therefore, the clinician and the radi-
ologist rely on the exclusion of other potential causes, and 
on the relationship between the onset of lung injury and the 
drug to make the correct diagnosis of TKI-induced ILD.
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